Table 1.
PD Patient and Control Demographics and Clinical Scores
| PD Patients | Subtype differences p-value | Healthy Controls (N=20) | PD vs Healthy Controls p-Value | |||
|---|---|---|---|---|---|---|
| All (N=21) | TD (N=12) | PIGD (N=9) | ||||
| Age (mean ± SD) | 61.1 ± 7.6 | 60.9 ± 8.3 | 60.2 ± 7.4 | 0.88 | 61.1± 8.8 | 0.97 |
| Gendera | 12M: 9 F | 9M: 3F | 3M: 6F | 0.06 | 11M: 9 F | 0.89 |
| MoCA | 27.7 ± 1.5 | 27.8 ± 1.5 | 27.6 ± 1.7 | 0.78 | 28.2 ± 1.7 | 0.30 |
| Education (years) | 16 ± 2.4 | 16.4 ± 1.4 | 15.3 ± 3.3 | 0.32 | 17 ± 1.9 | 0.20 |
| Hoehn & Yahr stage | 2.2 ± 0.7 | 2.0 ± .04 | 2.5 ± 0.9 | 0.08 | - | - |
| Disease duration (years) | 5.5 ± 3.4 | 5.2 ± 2.7 | 5.9 ± 4.3 | 0.63 | - | - |
| Levodopa Equivalent Daily Dose | 505 ± 367 | 559 ± 395 | 463 ± 360 | 0.58 | - | - |
| MDS-UPDRS Total | 53.6 ± 10.7 | 56.9 ± 10.3 | 49.3 ± 11.2 | 0.26 | - | - |
| MDS-UPDRS III–OFF | 31.4 ± 10.0 | 33.4 ± 9.9 | 28.7 ± 9.9 | 0.35 | - | - |
| MDS-UPDRS III–ON | 22.2 ± 9.6 | 23.5 ± 8.4 | 20.6 ± 11.4 | 0.50 | - | - |
| Neuropsychiatric Inventory-Severity | 2.6 ± 2.6 | 2.2 ± 1.8 | 3.1 ± 3.4 | 0.42 | - | - |
| Beck Depression Inventory | 8.2 ± 5.7 | 8.5 ± 5.3 | 7.8 ± 6.4 | 0.78 | - | - |
Abbreviations: PD Parkinson’s Disease; MDS-UPDRS Movement Disorders Society-Unified Parkinson’s Disease Rating Scale.
a
Gender comparison performed using Chi-squared test.